To explore the role of tertiary lymphoid structures (TLS) in the tumor microenvironment of pancreatic cancer and their potential as targets for immunotherapeutic strategies.
Key Findings:
The presence of TLS in the tumor microenvironment is linked to improved prognosis and patient outcomes.
There is a critical gap in understanding the mechanistic role of TLS components in clinical outcomes.
Preclinical studies suggest that TLS can enhance the efficacy of chemotherapy in pancreatic cancer models.
Interpretation:
Limitations:
Limited mechanistic understanding of TLS components and their interactions.
Poor elucidation of the temporal dynamics governing TLS in response to therapies.
Discrepancies between preclinical models and clinical outcomes regarding TLS induction.
